Glenmark Pharmaceuticals On Saturday Said It Has Launched Antiviral Drug Favipiravir, Under The Brand Name Fabiflu, For The Treatment Of Patients With Mild To Moderate Covid-19. The Mumbai-Based Drug Firm Had On Friday Received Manufacturing And Marketing Approval From The Drugs Controller General Of India (Dcgi).Fabiflu Is The First Oral Favipiravir-Approved Medication For The Treatment Of Covid-19, The Company Said In A Statement."This Approval Comes At A Time When Cases In India Are Spiralling Like Never Before, Putting A Tremendous Pressure On Our Healthcare System," Glenmark Pharmaceuticals Chairman And Managing Director Glenn Saldanha Said.The Company Hopes That The Availability Of An Effective Treatment Such As Fabiflu Will Considerably Help Assuage This Pressure, And Offer Patients In India A Much Needed And Timely Therapy Option, He Added.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!